← Back to Search

mTOR inhibitor

Topical Rapamycin for Inflammatory Mediators (Topical-RAPA Trial)

Phase < 1
Waitlist Available
Led By Dean L Kellogg, Jr., MD, PhD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights

Topical-RAPA Trial Summary

This trial will test whether epigenetic changes can be caused by using a topical ointment.

Eligible Conditions
  • Inflammatory Mediators
  • Aging
  • Epigenetics

Topical-RAPA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Epigenetic Markers
Secondary outcome measures
Change in Inflammatory Marker CRP
Change in Inflammatory Marker IL-6

Topical-RAPA Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Topical RapamycinActive Control1 Intervention
Ointment is applied to a color coded area on the subject forearm daily.
Group II: PlaceboPlacebo Group1 Intervention
Placebo ointment is applied to a color coded area on the subject forearm daily.

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,673 Previous Clinical Trials
28,020,817 Total Patients Enrolled
The University of Texas Health Science Center at San AntonioLead Sponsor
452 Previous Clinical Trials
91,388 Total Patients Enrolled
Dean L Kellogg, Jr., MD, PhDPrincipal InvestigatorUniversity of Texas Health at San Antonio

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment into this trial limited by age, and if so, what are the guidelines?

"This trial seeks out elderly patients aged between 65 and 95 years."

Answered by AI

What is the current number of participants enrolled in this clinical trial?

"At the present moment, this trial is not seeking participants. It was initially listed on April 28th 2021 and has been updated most recently on May 4th 2022. Alternatively, there are 590 clinical trials recruiting patients for epigenetic research and 126 that require volunteers to test Topical Rapamycin's efficacy."

Answered by AI

Is enrollment for this trial currently open to prospective participants?

"This clinical trial is not presently enrolling candidates. It was initially shared on April 28th 2021 and last updated May 4th 2022. If you are in search of other trials, there are 590 epigenetics-related studies calling for volunteers as well as 126 topical rapamycin investigations seeking participants."

Answered by AI

What precedent exists for using Topical Rapamycin in clinical testing?

"Currently, there are 126 trials exploring the efficacy of Topical Rapamycin. 13 of these studies have entered Phase 3 and 1075 different medical sites are running them. The largest concentration is in Cincinnati, Ohio area."

Answered by AI

Am I eligible to partake in this scientific investigation?

"This research is accepting 50 participants aged between 65 and 95 who possess epigenetic characteristics. To be accepted, applicants should meet certain criteria: they must have a CLOX score of 10 or greater; be postmenopausal (with the exception of those taking hormone replacement therapy for at least 6 months); live within 20 miles radius from UTHSA campus in San Antonio, TX; and demonstrate general wellbeing as defined by World Health Organization standards."

Answered by AI

What is the common rationale for administering Topical Rapamycin?

"Topical Rapamycin is frequently employed as a remedy for organ rejection, liver disease and renal angiomyolipomas."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock
Ellen Kraig 2021. "Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04608448.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top